Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) FCF Margin (2016 - 2025)

Arcadia Biosciences' FCF Margin history spans 12 years, with the latest figure at 95.56% for Q4 2025.

  • For Q4 2025, FCF Margin rose 8388.0% year-over-year to 95.56%; the TTM value through Dec 2025 reached 97.55%, up 9302.0%, while the annual FY2025 figure was 97.55%, 9305.0% up from the prior year.
  • FCF Margin reached 95.56% in Q4 2025 per RKDA's latest filing, down from 19.74% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41.38% in Q4 2022 to a low of 627.05% in Q1 2021.
  • Average FCF Margin over 5 years is 207.94%, with a median of 168.19% recorded in 2021.
  • Peak YoY movement for FCF Margin: skyrocketed 293482bps in 2021, then crashed -57561bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 156.93% in 2021, then soared by 126bps to 41.38% in 2022, then crashed by -1391bps to 534.23% in 2023, then soared by 66bps to 179.44% in 2024, then skyrocketed by 47bps to 95.56% in 2025.
  • Per Business Quant, the three most recent readings for RKDA's FCF Margin are 95.56% (Q4 2025), 19.74% (Q3 2025), and 139.73% (Q2 2025).